evidence table

Prebiotic Gut Comfort Randomized Trial Evidence Table

Structured evidence table for Prebiotic Gut Comfort Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.

topicclaimevidence levelcitationsource
Prebiotic Gut Comfort Randomized TrialPreclinical research, primarily in experimental animal models, has demonstrated a causal link between microbiota composition and developmental processes such as myelination, synaptic plasticity, and socio-emotional behaviors, whereas human evidence remains largely associative and heterogeneous.1Carnazzo SM (2026)Early-Life Microbiota Modulation and Neurodevelopment in Infants: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Prebiotic Gut Comfort Randomized TrialChanges in microbial composition during early infancy by various factors (mode of delivery, nutritional practices, antibiotic usage, and environmental influences) have been correlated with observable variances in cognitive abilities, temperament, stress response, and the predisposition to neurodevelopmental disorders.1Carnazzo SM (2026)Early-Life Microbiota Modulation and Neurodevelopment in Infants: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Prebiotic Gut Comfort Randomized TrialConsequently, microbiota-targeted interventions such as probiotics, prebiotics, and synbiotics are being explored as avenues to enrich beneficial microbial taxa, enhance short-chain fatty acid production, fortify mucosal immunity, and mitigate inflammatory responses during these critical periods.1Carnazzo SM (2026)Early-Life Microbiota Modulation and Neurodevelopment in Infants: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Prebiotic Gut Comfort Randomized TrialIt is postulated that, apart from genetic predisposition, the rise of local and systemic immune response in PS could be a consequence of intestinal dysbiosis associated with increased intestinal permeability.2Krupa-Kozak U (2026)INulin-type β-fructans supplementation to modulate gut microbiota and assessment of its effects on health status and GUT-SKIN axis parameters in patients with psoriasis (INGUTSKIN): the 8-week, randomised, double-blind, placebo-controlled clinical study protocol.
Prebiotic Gut Comfort Randomized TrialWe expect that the RCT results will enable the introduction of personalised dietary therapy with prebiotic ITFs, which, unlike other PS therapies, would not pose a high risk of side effects.2Krupa-Kozak U (2026)INulin-type β-fructans supplementation to modulate gut microbiota and assessment of its effects on health status and GUT-SKIN axis parameters in patients with psoriasis (INGUTSKIN): the 8-week, randomised, double-blind, placebo-controlled clinical study protocol.
Prebiotic Gut Comfort Randomized TrialBACKGROUND: A strong, bidirectional association exists between gastrointestinal health and skin homeostasis in many chronic skin inflammations, including psoriasis (PS).2Krupa-Kozak U (2026)INulin-type β-fructans supplementation to modulate gut microbiota and assessment of its effects on health status and GUT-SKIN axis parameters in patients with psoriasis (INGUTSKIN): the 8-week, randomised, double-blind, placebo-controlled clinical study protocol.
topicPrebiotic Gut Comfort Randomized Trial
claimPreclinical research, primarily in experimental animal models, has demonstrated a causal link between microbiota composition and developmental processes such as myelination, synaptic plasticity, and socio-emotional behaviors, whereas human evidence remains largely associative and heterogeneous.
evidence level1
citationCarnazzo SM (2026)
sourceEarly-Life Microbiota Modulation and Neurodevelopment in Infants: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
topicPrebiotic Gut Comfort Randomized Trial
claimChanges in microbial composition during early infancy by various factors (mode of delivery, nutritional practices, antibiotic usage, and environmental influences) have been correlated with observable variances in cognitive abilities, temperament, stress response, and the predisposition to neurodevelopmental disorders.
evidence level1
citationCarnazzo SM (2026)
sourceEarly-Life Microbiota Modulation and Neurodevelopment in Infants: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
topicPrebiotic Gut Comfort Randomized Trial
claimConsequently, microbiota-targeted interventions such as probiotics, prebiotics, and synbiotics are being explored as avenues to enrich beneficial microbial taxa, enhance short-chain fatty acid production, fortify mucosal immunity, and mitigate inflammatory responses during these critical periods.
evidence level1
citationCarnazzo SM (2026)
sourceEarly-Life Microbiota Modulation and Neurodevelopment in Infants: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
topicPrebiotic Gut Comfort Randomized Trial
claimIt is postulated that, apart from genetic predisposition, the rise of local and systemic immune response in PS could be a consequence of intestinal dysbiosis associated with increased intestinal permeability.
evidence level2
citationKrupa-Kozak U (2026)
sourceINulin-type β-fructans supplementation to modulate gut microbiota and assessment of its effects on health status and GUT-SKIN axis parameters in patients with psoriasis (INGUTSKIN): the 8-week, randomised, double-blind, placebo-controlled clinical study protocol.
topicPrebiotic Gut Comfort Randomized Trial
claimWe expect that the RCT results will enable the introduction of personalised dietary therapy with prebiotic ITFs, which, unlike other PS therapies, would not pose a high risk of side effects.
evidence level2
citationKrupa-Kozak U (2026)
sourceINulin-type β-fructans supplementation to modulate gut microbiota and assessment of its effects on health status and GUT-SKIN axis parameters in patients with psoriasis (INGUTSKIN): the 8-week, randomised, double-blind, placebo-controlled clinical study protocol.
topicPrebiotic Gut Comfort Randomized Trial
claimBACKGROUND: A strong, bidirectional association exists between gastrointestinal health and skin homeostasis in many chronic skin inflammations, including psoriasis (PS).
evidence level2
citationKrupa-Kozak U (2026)
sourceINulin-type β-fructans supplementation to modulate gut microbiota and assessment of its effects on health status and GUT-SKIN axis parameters in patients with psoriasis (INGUTSKIN): the 8-week, randomised, double-blind, placebo-controlled clinical study protocol.

Learn next

Related evidence and supplement guides

SupplementAkkermansia MuciniphilaA next-generation gut bacterium that plays a crucial role in strengthening the intestinal mucin...SupplementProbioticsLive beneficial bacteria that support digestive health, immune function, and the gut-brain axis.GuidePrebiotic Gut Comfort Randomized Trial: What the Evidence SaysPrebiotic Gut Comfort Randomized Trial has 2 source documents in the current Migaku evidence dat...GuideInulin Gut Comfort Randomized Trial: What the Evidence SaysInulin Gut Comfort Randomized Trial has 2 source documents in the current Migaku evidence databa...GuideBoswellia Joint Comfort Randomized Trial: What the Evidence SaysBoswellia Joint Comfort Randomized Trial has 2 source documents in the current Migaku evidence d...GuideAloe Vera Gut Health Randomized Trial: What the Evidence SaysAloe Vera Gut Health Randomized Trial has 2 source documents in the current Migaku evidence data...RankingBest Probiotics for Gut Health: 2026 Evidence Review & RankingsWe analyzed over 25 probiotic brands to find the best formulations containing scientifically val...RankingBest Gut Health Supplements 2026: Ranked by EvidenceThe gut health supplement market is full of overclaimed products. These have the strongest evide...

Source documents

  1. Early-Life Microbiota Modulation and Neurodevelopment in Infants: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
  2. INulin-type β-fructans supplementation to modulate gut microbiota and assessment of its effects on health status and GUT-SKIN axis parameters in patients with psoriasis (INGUTSKIN): the 8-week, randomised, double-blind, placebo-controlled clinical study protocol.